NAVAN Technologies

NAVAN Technologies is a private, pre-revenue biotech company commercializing its patented NanoStraw platform for intracellular delivery and extraction. The core technology uses physical, nanostraw conduits to transport a wide variety of cargos (DNA, mRNA, proteins) into primary cells with high efficacy and cell viability, positioning it as a potential enabler for next-generation cell and gene therapies. NAVAN is pursuing a platform business model, actively developing therapies in oncology and other areas through strategic partnerships, rather than as a standalone therapeutic developer.

NanoStraws: a physical, non-perturbative intracellular delivery platform using vertical nanostraw conduits to gently deliver diverse cargos (DNA, mRNA, proteins) into primary cells with high viability and precise dosage control.

NAVAN competes in the intracellular delivery space against viral vector companies, electroporation-based systems (e.g., MaxCyte, Lonza), and other non-viral methods like lipid nanoparticles (LNPs) and cell squeezing. Its differentiation is a physical, gentle mechanism claiming superior viability and versatility for primary cells.